• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    OncBioMune Applies to Commercialize Anti-Rabies Drug in Mexico

    Bryan Mc Govern
    Aug. 03, 2017 08:49AM PST
    Pharmaceutical Investing

    OncBioMune Pharmaceuticals submitted an application with the Mexican equivalent of the US Food and Drug Administration to commercialize a licensed anti-rabies drug.

    OncBioMune Pharmaceuticals (OTCQB:OBMP) submitted an application with the Mexican equivalent of the US Food and Drug Administration to commercialize a licensed anti-rabies drug.
    As quoted in the press release:

    The License Partner has granted OncBioMune an exclusive license for the anti-rabies drug for the Mexican market. The License Partner and product brand are being kept confidential for competitive reasons at this time.
    The injectable anti-rabies immunoglobulin (human) is currently sold throughout the world, including Brazil, Argentina, Colombia and Peru. It is indicated for passive, transient post-exposure prophylaxis against rabies infection administered after exposure / contact with an animal suspected of being infected with rabies, a viral infection caused by viruses belonging to the Lyssavirus genus. The treatment has yet to be commercialized in Mexico.
    “This is a popular anti-rabies therapeutic throughout South America and we are excited with the submission seeking to commercialize it in Mexico under the OncBioMune umbrella,” commented Manuel Cosme Odabachian, General Manager of Global Operations at OncBioMune. “Rabies prevalence in Mexico is quite high and we believe that we will able to be competitive in the bid/tender process to capture our fair share of market. We are optimistic that we will be selling the product in 2018 and estimate annual demand in the range of 10,000 to 20,000 units, making it a strong complement to our other revenue-generating assets.”

    Click here to read the full press release.

    argentinapharmaceutical investingoncbiomune pharmaceuticalsbrazilus food and drug administrationexclusive licensefood and drug administration
    The Conversation (0)

    Go Deeper

    AI Powered
    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×